Jefferies Group set a €125.00 ($154.32) price target on Bayer (FRA:BAYN) in a research report report published on Tuesday, January 16th. The brokerage currently has a buy rating on the healthcare company’s stock.
BAYN has been the topic of several other reports. S&P Global set a €126.00 ($155.56) target price on Bayer and gave the company a buy rating in a research report on Thursday, October 26th. Sanford C. Bernstein set a €131.00 ($161.73) price target on Bayer and gave the company a buy rating in a research note on Wednesday, November 29th. DZ Bank reiterated a buy rating on shares of Bayer in a research note on Monday, December 11th. equinet set a €118.00 ($145.68) price target on Bayer and gave the company a buy rating in a research note on Friday, October 13th. Finally, BNP Paribas set a €130.00 ($160.49) price target on Bayer and gave the company a buy rating in a research note on Monday, September 25th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the stock. The company presently has an average rating of Buy and an average target price of €121.71 ($150.26).
Shares of Bayer (FRA BAYN) traded down €1.48 ($1.83) during trading hours on Tuesday, reaching €96.14 ($118.69). The company had a trading volume of 6,034,400 shares. Bayer has a 12 month low of €93.30 ($115.19) and a 12 month high of €123.82 ($152.86). The firm has a market cap of $78,820.00 and a price-to-earnings ratio of 22.73.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.